...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.
【24h】

HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.

机译：乳房的her - 2:一个生物标志物在十字路口癌症免疫治疗和分子医学。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosine kinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.
机译：由her - 2致癌基因是编码的癌蛋白她的家庭成员的受体酪氨酸激酶,实际上是第一个成功利用目标分子在新的生物分子治疗实体肿瘤。her - 2过表达与人类肿瘤,其细胞外的可访问性,以及它的参与肿瘤侵犯因素,使这个受体合适肿瘤特异性治疗的目标。her - 2过表达促进其免疫原性,如图所示,B和T的频率细胞介导的反应对肿瘤蛋白在癌症患者,它正在调查中作为被动和有前途的分子主动免疫治疗策略。总结了大量的免疫干预方法目标her - 2在乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号